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Abstract 
Kidney transplantation is the optimal treatment for patients with end stage 
renal disease (ESRD) who would otherwise require dialysis. Patients with 
ESRD are at dramatically increased cardiovascular (CV) risk compared to the 
general population. As well as improving quality of life, successful 
transplantation accords major benefits by reducing cardiovascular risk in 
these patients. Worldwide, cardiovascular disease remains the leading cause 
of death with a functioning graft and therefore is a leading cause of graft 
failure. This review focuses on the mechanisms underpinning excess 
cardiovascular morbidity and mortality and current evidence for improving 
cardiovascular risk in kidney transplant recipients. Conventional 
cardiovascular risk factors such as hypertension, diabetes mellitus, 
dyslipidaemia, and pre-existing ischaemic heart disease are all highly 
prevalent in this group. In addition, kidney transplant recipients exhibit a 
number of risk factors associated with pre-existing renal disease. 
Furthermore, complications specific to transplantation may ensue including 
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reduced graft function, side effects of immunosuppression and post 
transplantation diabetes mellitus. Strategies to improve cardiovascular 
outcomes post transplantation may include pharmacological intervention 
including lipid lowering or antihypertensive therapy, optimisation of graft 
function, lifestyle intervention and personalising immunosuppression to the 
individual patients risk profile. 
 
Background 
Transplantation confers the highest survival benefit among all the different 
renal replacement therapies. Multiple studies have shown that patient survival 
is better with renal transplantation than with maintenance dialysis after an 
increased risk of death in the early period after transplantation[1-5]. This is 
true for patient groups who are otherwise at increased cardiovascular (CV) 
risk including diabetics, African Americans, all age groups[3], obese 
patients[6], as well as recipients of marginal kidneys[7-9] and following repeat 
renal transplantation after failed primary transplantation[10, 11]. Although 
long-term allograft survival has improved, death with a functioning graft 
remains the leading cause of late renal allograft loss[12, 13]. Cardiovascular 
disease (CVD) persists as the leading cause of premature death in most 
kidney transplant registries[14].  
Knowledge of the incidence, risk factors and the natural history of CVD in 
renal transplantation derives from registry data, observational population-
based studies, clinical trials and extrapolation from studies on non-transplant 
cohorts. This review focuses on describing the nature of CVD in renal 
transplant recipients (RTR), including dissecting the various components, 
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which combine as the syndrome of CVD in RTR. We highlight evidence based 
treatments for reducing cardiovascular risk where this exists.  
 
Epidemiology of cardiovascular disease in kidney transplantation 
CVD mortality in haemodialysis (HD) patients is 10 to 20 times greater than in 
the general population[15]. Renal transplant recipients have lower risk for 
CVD than patients who remain on the transplant waiting list, but higher CVD 
risk when compared with the general population[16], particularly those aged 
25–55 years who have substantially more CVD mortality than their age-, 
gender-, and race-matched non-dialysis counterparts. Registry data show that 
cardiac disease is the cause of death for 18-30% of prevalent transplant 
patients[17, 18]. Recent UK Registry data of 566 deaths (3.0%) within the first 
year post transplant (from 19,103 kidney transplants performed over an 11-
year period) demonstrates that whilst infection was the single leading cause of 
death (21.6% of deaths) in the first year post transplant, cardiovascular events 
combined with cerebrovascular disease accounted for the greatest proportion 
of deaths at 22.9%[19]. With longer follow up CVD continues to accumulate 
and accounts for 31% of deaths with a functioning graft in the 2013 United 
States Renal Data System (USRDS) Report [17]. 
 
Clinical aspects of cardiovascular disease in kidney transplantation 
In the general population CVD predominantly relates to underlying coronary 
artery atherosclerosis and is associated with conventional cardiovascular risk 
factors such as hypertension, dyslipidaemia, diabetes, cigarette smoking and 
family history. This paradigm does not hold true for patients with ESRD where 
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sudden, presumed arrhythmic, cardiac death rather than myocardial infarction 
(MI) is the predominant mode of cardiovascular mortality.  The paradox of 
reverse epidemiology is acknowledged in ESRD patients on dialysis where J-
shaped (rather than linear) relationships are seen between blood 
pressure[20], cholesterol[21] and body mass index[22] and mortality risk. 
Following successful transplantation patients with ESRD have more 
conventional relationships between cardiovascular risk factors and outcome, 
as illustrated recently by post hoc analysis of the Folic Acid for Vascular 
Outcome Reduction in Transplantation [23] [23] trial[24], where there was a 
linear relationship between increasing systolic blood pressure and mortality. 
Although, more conventional relationships between CVD and risk factors 
evolve post transplantation, legacy of time spent on dialysis remains. Along 
with diabetes and age, evidence of left ventricular hypertrophy with ‘strain’ on 
the ECG, often associated with longstanding ESRD was associated with 
increased risk of cardiac death in the Assessment of Lescol in Renal 
Transplantation (ALERT) trial[25].   
 
Whilst the relationship between risk factors and CV events reverts towards the 
general population, the outcomes following a CV event in RTR are not 
comparable with the general population. In the ALERT study[26], there was a 
similar rate of fatal and non-fatal CV events to other randomised controlled 
trials of lipid lowering therapy(WOSCOPS[27] and 4S[28]).  In non-transplant 
populations non-fatal CV events are more common than fatal events. 
Therefore in RTR, risk of CVD is increased and there is a high prevalence of 
CV risk factors. There are dichotomous patterns of CVD in RTR, including 
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both atheromatous coronary artery disease (CAD) as seen in the general 
population and sudden cardiac death as observed in dialysis patients. When 
they occur, CV events are more likely to be fatal than in the general 
population.  
 
Coronary artery disease 
Coronary artery disease influences listing for transplantation. At the time of 
transplantation, prior MI suggesting occlusive CAD is reported in 2.6% of 
transplant recipients in the UK [19]. Estimating prevalence of non-occlusive 
coronary artery atherosclerosis prior to transplantation is more difficult as 
most reports favour only performing coronary angiography in higher risk 
transplant candidates (e.g. over aged 50, diabetes mellitus, prior MI). 
Nonetheless, it appears that coronary artery atheroma is present in 
approximately 50% of higher risk transplant candidates[29]. Performing 
unselected coronary angiography appears to lead to low rates of coronary 
intervention in renal transplant candidates and is unlikely to be a useful 
strategy for risk reduction pre-transplantation[30, 31].   
Once transplanted, prevalent CVD accumulates and was reported in 20% 
(14% previous MI or CAD) of participants at study entry in the FAVORIT 
trial[32] compared to 11.5% (4.7% previous MI, 6.8% revascularisation 
procedure) of participants in the observational PORT study[33]. US data[17] 
show that hospitalisations for coronary atherosclerosis increases from 5.5% in 
year one to 9% in year two. Lentine et al[34] concluded that post 
transplantation MI is common, affecting approximately 11.1% of patients by 3 
years post transplantation, and that much of this risk is experienced early, 
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within the first 6 months of transplantation. MI risk was linked with modifiable 
factors, including delayed graft function, post transplantation diabetes, and 
graft failure, and in turn, occurrence of MI predicted graft failure and death. 
Additionally, post hoc analyses of the ALERT trial[25] demonstrated that, 
determinants of non-fatal myocardial infarction in RTR include total 
cholesterol level, prior CAD and previous acute rejection. Combined, these 
data suggest that whilst RTR share common risk factors with the general 
population for CAD and MI post transplantation; there are further graft-specific 
aspects to post transplant CAD.  
 
Congestive heart failure 
Congestive heart failure (CHF) and renal dysfunction form a “vicious circle” 
that augur poor prognosis. At commencement of dialysis, up to 70% of 
patients with ESRD may have abnormal cardiac structure or function[35]. 
Transplantation may decrease the risk for CHF specifically compared with 
dialysis therapy[36]. However, CHF remains a clinical concern after 
transplantation. Wali et al[37] showed an improvement of left ventricular (LV) 
systolic function in more than 86% of patients following kidney transplantation 
which was associated with an improvement in NYHA functional status in more 
than two-thirds of patients. Duration of dialysis therapy before transplantation 
was the only factor that predicted normalisation of LV systolic dysfunction. 
Lentine et al[38] examined incidence of de novo CHF in 27,011 transplant 
recipients. Cumulative incidences of CHF were 10.2% and 18.3% at 1 and 3 
years post transplantation and beyond the early post transplantation period,  
incidence of new onset CHF decreased progressively to less than the 
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incidence in transplant candidates (18.3% versus 32.3% at 3 years). US 
data[17] show that cardiovascular hospitalisations due to congestive heart 
failure rise from 21% in the first post transplant year to 25% in the second 
year. 
 
Arrhythmia 
Despite the high incidence of sudden cardiac death, surprisingly little is known 
about arrhythmias in RTR. This reflects the difficulty in capturing short-lived 
arrhythmic episodes in asymptomatic patients. Using 24-hour ECG 
monitoring, RTR have been shown to have higher rates of ventricular 
arrhythmia, usually ventricular extra systoles, compared to patients with mild 
chronic kidney disease (CKD)[39]. Ventricular repolarisation is also abnormal, 
usually due to underlying left ventricular hypertrophy (LVH). Whilst ventricular 
arrhythmia when sustained is life threatening, atrial arrhythmia, in particular 
atrial fibrillation and flutter are relatively common (6.4% of US transplant 
recipients[40]), and confers increased risk of ischaemic stroke. Patients with 
atrial fibrillation are likely to be older and have greater co-morbidity 
burden[40]. There are no specific guidelines or studies to inform therapeutic 
strategies in RTR with atrial fibrillation. 
 
Risk factors for development of CVD in kidney transplantation 
The burden of CVD in RTR is not entirely explained by traditional risk factors 
such as hypertension, dyslipidaemia, and diabetes[16]. Other factors may be 
involved, particularly those that influence systemic inflammation including 
graft rejection, infection, and use of immunosuppressive medications[13, 41].  
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Standard CVD risk calculators for the general population are poorly predictive 
in RTR. Soveri et al developed a formula for 7-year CVD and mortality risk 
calculation for prevalent RTR[42] using models with different variables 
including age, CAD, diabetes, low-density lipoprotein (LDL), creatinine, 
number of transplants, time on renal replacement therapy, and smoking 
(http://www.anst.uu.se/insov254/calculator/). Carpenter et al[32] demonstrated 
that traditional CVD risk factors are inadequately managed in RTR. Using 
baseline data from the FAVORIT study, they showed that almost a third of the 
patients did not meet blood pressure (BP) target of <130/80mmHg, one to five 
had borderline or elevated LDL cholesterol and a third of the participants with 
prevalent CVD were not using an antiplatelet agent for secondary prevention. 
 
Hypertension 
Hypertension is common after kidney transplantation and is present in 50% to 
90% of RTR [43, 44]. Multiple factors induce susceptibility to high blood 
pressure (BP) after transplantation including recipient, donor and transplant 
factors, immunotherapy, transplant dysfunction, renal artery stenosis and 
obstruction[45]. Hypertension is a leading cause for both decline in graft 
function and development of CVD[13, 16, 41, 46]. The influence of blood 
pressure on long-term kidney graft outcomes was demonstrated in the 
Collaborative Transplant Study (CTS)[47]. Increased blood pressure at 
different time intervals post transplantation was associated with late graft 
failure. Subsequent studies[43, 48] showed that this strong, graded 
relationship between post transplant BP and renal allograft failure was 
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independent of acute rejection and baseline renal function, thus suggesting 
that progressive renal dysfunction was the result of elevated BP. 
BP control in RTR is particularly challenging. Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines[49] recommend a BP target of ≤130/80 
mmHg irrespectively of level of proteinuria. This is based on data from patient 
subgroups in the general population rather than data in RTR. Retrospective 
data[50] showed that systolic BP of ≤140 mm Hg at 3 years after 
transplantation is associated with improved graft survival and reduced 
cardiovascular mortality at 10 years and this effect remained even after 
lowering systolic BP several years post transplantation. 
 
Vasoconstriction is the dominant mechanism by which calcineurin inhibitors 
(CNI) induce acute nephrotoxicity and hypertension, thus, dihydropyridine 
calcium-channel blockers (CCB) are an attractive option at least for the early 
management of hypertension after transplant. The beneficial effect of CCB on 
kidney function, compared with either placebo or angiotensin converting 
enzyme inhibitors (ACEi), was shown in short-term randomised controlled 
trials (RCT)[51-54] although effects of CCB on long-term kidney function in 
CNI–treated RTR have been reported with variable efficacy[55-57]. A recent 
meta-analysis of randomised controlled trials[58] indicated that use of CCB, 
versus placebo or no treatment (plus additional agents in either arm, as 
needed) was associated with 25% lower rate of graft loss and higher 
glomerular filtration rate (GFR) and in direct comparison with ACEi, CCB 
significantly improved GFR by approximately 12ml/min. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
ACEi may reverse post transplant erythrocytosis, decrease proteinuria and 
have a theoretical effect in mitigating antibody-mediated rejection mediated by 
antibody to AT1 receptor. In a RCT of renal transplant recipients with LVH[59], 
patients administered ACEi had significantly better general and cardiovascular 
outcome after 10-year follow-up, suggesting that the effect by renin-
angiotensin-system (RAS) blockade on clinical outcome can only be observed 
with longer follow-up. Another RCT that was adequately powered to assess 
hard outcomes in comparison between RAS blockade and placebo in RTR[60] 
was prematurely discontinued after 2 years because the incidence of events 
was considerably lower than expected in both arms of the study.  
Finally, two recent meta-analyses[61, 62] pointed out advantages of adopting 
calcium channel blockers for blood pressure control in RTR because RAS 
blockers are associated with progressive worsening of renal graft function 
without benefit in CV risk. Patients on ACEi or angiotensin receptor blockers 
(ARB) had a decrease in glomerular filtration rate (5.8ml/min), lower 
haematocrit (3.5% translating to haemoglobin lowering of approximately 1.2 
g/dl) and reduction in proteinuria[61]. The rate of cardiovascular death was 
similar in patients who received ACEi/ARB therapy or other antihypertensive 
treatment overall and in subpopulations of patients known to be at high 
cardiovascular risk[62]. 
 
Dyslipidaemia 
Almost half of the RTR have low density lipoprotein (LDL) cholesterol levels 
>2.6mmol/L and 41% are on statin treatment six months post 
transplantation[63]. Dyslipidaemia is common after transplantation, partly due 
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to the hyperlipidaemic effect of corticosteroids, cyclosporine, tacrolimus, and 
mammalian target of rapamycin (mTOR) inhibitors. In the CONVERT trial[64], 
conversion from cyclosporine or tacrolimus to rapamycin was associated with 
higher prevalence of hypertriglyceridemia (54 versus 26%) and 
hypercholesterolemia (42 versus 12%) by month 24, even in the context of 
more common use of lipid-lowering therapy (78 versus 55%). On the contrary, 
converting from cyclosporine to tacrolimus may provide significant benefits in 
serum lipid levels[65]. 
 
The Assessment of Lescol in Renal Transplantation (ALERT) trial[26] was the 
first large study to address cardiac and renal outcomes in transplantation. 
Treatment with fluvastatin (40-80mg) failed to reach statistical significance in 
the primary composite end points (major adverse cardiac events defined as 
cardiac death, non-fatal MI, and coronary intervention) despite 32% lowering 
of LDL cholesterol during a mean follow-up of 5.1 years. On the “hard” 
cardiovascular endpoints, treatment with fluvastatin demonstrated a reduction 
of 38, 32 and 35% in the risk of cardiac death, non-fatal MI and in the 
cumulative incidence of cardiac death or first non-fatal MI respectively. 
Nonetheless, a 2-year extension to the original study[66] demonstrated 
significant long-term benefits in the primary composite outcome. Post hoc 
analyses of the ALERT study demonstrated that early initiation of lipid-
lowering therapy had a more favourable effect on cardiac events than late 
intervention[67] and lowering of LDL cholesterol by 39mg/dL reduced cardiac 
death or myocardial infarction by approximately 30%[68]. 
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Long-term treatment with fluvastatin was well tolerated and had no harmful 
effects on renal function. This was opposed with previous reports[69] 
highlighting increased risk of myopathy and rhabdomyolysis, especially when 
co-administered with cyclosporine, which often results in several-fold 
increases in statin blood level. 
Additionally, a Cochrane meta-analysis of 22 studies[70] including 3,465 RTR 
confirmed the CV benefits of statins. The 2013 KDIGO guidelines[71] suggest 
initial evaluation of all transplant patients with a lipid profile, without  follow-up 
lipid levels for the majority of patients since the indication for treatment is the 
higher cardiovascular risk, rather than LDL concentration.  
 
Post transplantation diabetes mellitus 
Post transplantation diabetes mellitus (PTDM) is increasing in incidence and 
is a major challenge following solid organ transplantation[72, 73]. 
Approximately one-third of non-diabetic kidney transplant recipients develop 
persistently impaired glucose metabolism by six months post 
transplantation[74]. At 3 years, the cumulative incidence of post transplant 
diabetes amongst RTR is between 24.0% and 42.0%[17, 75]. Risk factors for 
PTDM include age, obesity, African American race and Hispanic ethnicity, 
family history and impaired glucose tolerance[76]. In addition, risk factors that 
are unique to transplantation include immunosuppressive agents, HLA 
mismatch, donor gender, type of underlying renal disease and viral infections 
(HCV and CMV)[76, 77]. Both PTDM and impaired glucose tolerance [65] 
confer a higher risk of developing CVD. The increased relative risk for death 
from CVD ranges from 1.5 to 3 among those who develop PTDM versus 
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those without diabetes[75, 78]. In a cohort study of 37,448 RTR[79], pre-
existing diabetes was associated with higher cardiovascular and overall 
mortality compared with post transplantation diabetes mellitus, at least shortly 
after transplantation. 
 
Renal impairment 
Reduced kidney function is a risk factor for CVD in the general population, in 
part reflecting the close association of CVD risk factors and GFR. Population 
data[80] suggest that even minor kidney dysfunction is associated with 
increased cardiovascular risk. The relationship of GFR with CVD risk in 
transplant recipients may differ following transplantation, because the level of 
GFR may no longer reflect lifelong exposure to CVD risk factors[13]. A post 
hoc analysis of 1,052 participants in the ALERT Study[25], showed that renal 
dysfunction was associated with fatal CVD. Mild renal insufficiency was 
independently associated with increased risk of acute coronary syndromes 
and CHF[81], and 15% higher risk of CVD and death for each 5ml/min/1.73m2 
lower eGFR (at levels below 45ml/min/1.73m2)[82].  
 
Left ventricular hypertrophy 
LVH is present in 50-70% of patients following renal transplantation[16] and is 
a significant risk factor for CHF and death in RTR[83]. Correction of the 
uraemic state by transplantation leads to a fall in LV mass with 
echocardiographic examination[84, 85] though when LV mass was measured 
by the more accurate cardiac magnetic resonance[86], renal transplantation 
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was not associated with significant regression of LV mass suggesting that 
improvement in fluid balance leads to apparent improvement in LV mass. 
LVH is primarily an adaptive response to volume and pressure overload with 
the aim of minimising ventricular wall stress. Multiple risk factors contribute to 
LVH development including age, hypertension, hypercholesterolemia, tobacco 
smoking, obesity, or diabetes, as well as transplant-specific risk factors 
including anaemia, the arteriovenous fistula flow, and immunosuppressive 
therapy[87]. Resistance to left ventricular outflow produced by aortic valve 
calcification during dialysis[88], anaemia and high blood pressure[89] appear 
to be leading contributors to development, progression and persistence of 
LVH in RTR. ACEi are effective in reversing LVH persisting despite successful 
renal transplantation, probably by reducing BP[90] but also through 
mechanisms that are at least partially independent of hemodynamic effects on 
BP[91]. In one study[91], ACEi were effective in regressing post 
transplantation LVH only in patients on cyclosporine therapy, perhaps 
because of an interaction effect between the two treatments. This indicates 
that immunosuppressive agents might modulate the effect of antihypertensive 
therapy on the left ventricular mass of RTR.  
 
The mTOR inhibitors play a role in regulating cell growth and may be a 
therapeutic tool to regress established cardiac hypertrophy. In two small 
studies, both sirolimus[92] and everolimus[93] regressed LVH in RTR 
regardless of BP changes, mainly by decreasing left ventricular wall 
thickness, suggesting non-hemodynamic effect mechanisms of mTOR 
inhibitors on left ventricular mass.  
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Effects of immunosuppression on cardiovascular risk 
Corticosteroids 
Corticosteroids have been a cornerstone of transplant immunosuppression for 
over 50 years, both as maintenance immunosuppression and for treatment of 
acute rejection. However, adverse effects of corticosteroids, mainly 
cardiovascular, have led to attempts to find maintenance immunosuppression 
regimens that do not include corticosteroids. Different protocols have been 
developed including ‘steroid-free’ protocols which do not use steroids as initial 
or maintenance immunosuppression, ‘steroid avoidance’ protocols in which 
steroids are initially used and are then withdrawn during the first week after 
transplantation, and ‘steroid withdrawal’ protocols in which steroids are 
discontinued weeks to months after transplantation.  
Cardiovascular risk in RTR varies with comorbidities such as pre-existing 
metabolic syndrome, race and age and in addition, many of the adverse 
effects attributed to corticosteroids were observed with high doses. Whether 
the low doses commonly used for maintenance immunosuppression are 
associated with major adverse effects is less clear and is difficult to dissociate 
the CV profile of steroids from other factors, such as underlying renal function 
and CNI use. 
 
Calcineurin inhibitors 
CNI-sparing maintenance immunosuppression regimens have been applied to 
help maintain the balance between allograft survival and nephrotoxicity. CNI 
raise arterial blood pressure in transplant recipients by several mechanisms, 
including arteriolar vasoconstriction, activation of the renin-angiotensin 
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system, direct effects on juxtaglomerular cells, and increased tubular sodium 
reabsorption[94, 95]. The beneficial effects of late CNI withdrawal on 
ambulatory blood pressure were documented in a recently published RCT of 
119 stable RTR on a triple-drug regimen[96]. 
Complete CNI withdrawal after the initial period of high immunological risk is 
attractive, however, this has been associated with an increased incidence of 
late acute rejection and a possible reduction in long-term allograft survival[97]. 
Trials that explored the switching from CNI to mTOR inhibitors 3 to 6 months 
post transplant[98-100] have shown the relative safety of this approach with 
improvement in renal function and blood pressure despite increased risk of 
acute rejection. 
 
Lifestyle and other cardiovascular risk factors in kidney transplant 
recipients 
Cigarette smoking increases the risk for graft failure[101, 102], ischaemic 
heart disease[102], and CHF[38] in renal transplant recipients. Prevalence of 
cigarette smoking at time of transplantation varies between 25% and 
50%[101, 102]. Between smokers RTR, graft failure is largely due to death 
with a functioning graft[102] and having quit smoking more than 5 years 
before transplantation reduced the relative risk of graft failure by 34%[102]. In 
the general population, there is strong evidence that screening patients for 
tobacco use and implementing prevention and treatment measures are 
effective. Guidelines suggest that the same approach should be applied for 
the RTR[103, 104]. 
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Obesity among transplant recipients is associated with the metabolic 
syndrome, which is present in two-thirds of RTR at six years post 
transplant[105]. Registry data show that obesity is associated with adverse 
cardiovascular outcomes including increased risk of cardiac death[106], 
CHF[81] and atrial fibrillation[107]. Lifestyle changes based in diet and 
exercise, with dietary counselling as needed, are first-line strategies to 
achieve normal body weight among obese RTR. There is a paucity of data on 
the safety and efficacy of post transplantation gastric banding or bypass 
surgery in ameliorating comorbid conditions such as hypertension, diabetes 
mellitus, and dyslipidaemia. 
 
Although low physical activity is strongly associated with increased risk for 
cardiovascular and all-cause mortality in RTR[108], the effect of exercise 
training in the cardiovascular risk profiles of RTR are unclear. A recent meta-
analysis of exercise training in solid organ transplant recipients[109] (including 
two RCT with 164 RTR) showed no significant improvements in exercise 
capacity or cardiovascular risk factors such as incidence of PTDM, indicating 
that exercise training is a promising but unproven intervention for improving 
the CV outcomes in RTR. 
Homocysteine is implicated to be an atherogenic amino acid and fasting 
hyperhomocysteinaemia has been shown to be an independent predictor of 
cardiovascular events among RTR[110]. However, in the Folic Acid for 
Vascular Outcome Reduction in Transplantation [23] trial[111], lowering 
homocysteine levels has not been shown to decrease cardiovascular risk 
among 4,110 RTR treated with vitamin B6 and vitamin B12 and with either 
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high or low dose folic acid, despite the fact that homocysteine was effectively 
lowered with high dose folic acid. 
Multiple other non-traditional risk factors have been associated with increased 
cardiovascular risk in various studies including anaemia, dialysis vintage prior 
to transplantation, elevated levels of lipoprotein a, elevated C-reactive protein 
and interleukin-6 levels[46, 112-114]. 
 
Conclusions 
Renal transplantation is the single most effective intervention for reducing 
cardiovascular risk in appropriately selected patients with ESRD. 
Nonetheless, CVD is common and is the leading cause of death with a 
functioning graft and hence graft loss. Strategies targeting modifiable 
conventional cardiovascular risk factors (diabetes, hypertension, 
dyslipidaemia and lifestyle) are crucial to reducing post transplant CVD. 
However further strategies to address transplant specific cardiovascular risk 
factors should also be employed. These should include optimisation of renal 
function, limiting risk of rejection, avoidance of PTDM and anticipation of 
cardiovascular side effects of immunosuppression. Further studies are 
required to address how each of these strategies is tailored to the 
requirements of the individual patient and graft.  
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Table 1 
 
 
Modifiabl
e risk 
factors 
for post 
transplant 
CVD 
Pre 
transplan
t hazard 
Post 
transplant 
exacerbati
on 
Potential 
strategies 
to 
address 
Rationale Studies 
Hypertensi
on 
Recipient, 
donor and 
transplant 
factors 
Immunothe
rapy, 
transplant 
dysfunction
, renal 
artery 
stenosis 
 
Target 
BP≤130/80
, avoid 
ACEi/ARB 
within the 
first 3 
months 
post 
transplanta
tion, 
consider in 
the long-
term 
especially 
if 
persistent 
albuminuri
a, LVH or 
other 
indications 
No 
evidence 
for benefit 
of any 
particular 
antihyperte
nsive agent 
Small 
RCT[51-
54, 57, 59] 
 
Observatio
nal 
data[43, 
46-48, 50] 
Post 
transplant
ation 
diabetes 
mellitus 
African 
American 
or 
American 
Hispanic 
ethnicity, 
obesity 
Immunothe
rapy, HLA 
mismatch, 
viral 
infections 
 
Target 
HbA1c 7.0-
7.5%, early 
basal 
insulin, 
incretin-
based 
therapy, 
steroid 
reduction 
or 
withdrawal, 
switch 
from 
tacrolimus 
to CsA 
Chances of 
reversing or 
amelioratin
g PTDM 
may be 
improved 
by early 
detection 
and 
intervention 
Small 
RCT[115, 
116] 
 
Observatio
nal 
data[75, 
78, 79] 
Left 
ventricular 
hypertroph
y 
Hyperten
sion, 
aortic 
valve 
calcificati
Immunothe
rapy 
 
ACEi, CsA, 
mTOR 
inhibitors 
 
Regression 
of LVH with 
BP 
decrease, 
other 
Small 
RCT[90, 
91, 93] 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
on, 
anaemia, 
dialysis, 
AVF flow 
mechanism
s 
independen
t of 
haemodyna
mic effects 
on BP 
Dyslipidae
mia 
Pre 
transplant 
lipid 
abnormali
ties 
Hyperlipemi
c effect of 
immunother
apy 
Statins, 
replace 
CsA by 
tacrolimus, 
avoid 
sirolimus, 
low dose 
prednisolo
ne 
Statins 
improve CV 
outcomes, 
no benefit 
in overall 
mortality, 
remarkably 
safe 
ALERT[26, 
66] 
 
Post hoc 
analyses[6
7, 68] 
Renal 
impairmen
t 
Previous 
graft loss, 
transplant 
factors 
CNI 
nephrotoxic
ity, AR 
episodes, 
proteinuria 
Optimisatio
n of graft 
function, 
CNI 
minimisatio
n to 
achieve 
adequate 
IS 
Mild renal 
insufficienc
y is 
associated 
with 
adverse CV 
outcomes 
Post hoc 
analyses[2
5, 82] 
 
Observatio
nal 
data[81] 
Calcineuri
n inhibitors 
Transplan
t factors 
Nephrotoxi
c, PTDM, 
Hypertensi
on, 
Dyslipidae
mia 
CNI dose 
reduction 
after the 
first 3 
months, 
conversion 
from CNI 
to mTOR 
inhibitors 3 
to 6 
months 
post 
transplant 
is relatively 
safe 
CNI 
withdrawal 
leads to 
increased 
acute 
rejection 
RCT[96, 
100] 
Corticoster
oids 
Diabetes, 
race 
PTDM, 
Hypertensi
on, 
Dyslipidae
mia 
Low dose 
steroids in 
the long-
term, 
discontinu
ation could 
be 
attempted 
in patients 
at 
No clear 
benefit for 
improved 
patient or 
graft 
outcomes 
after early 
or late 
discontinuat
ion of 
Short- and 
medium-
term 
RCT[117-
121] 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
increased 
CV risk 
with low 
immunolog
ical risk 
and stable 
allograft 
function 
steroids
Other CV 
risk factors 
Smoking, 
obesity, 
low 
physical 
activity, 
anaemia 
Immunothe
rapy, 
systemic 
inflammatio
n 
Quit 
smoking, 
diet, 
correction 
of anaemia
Unclear 
benefits of 
exercise 
and 
vitamins 
RCT[111] 
 
Observatio
nal 
data[102, 
106, 108] 
 
Extrapolati
on from 
studies in 
the general 
population[
103] 
 
Figure 1. Pre and post transplant factors conferring increased cardiovascular 
risk after kidney transplantation. 
BMI, body mass index; CNI, calcineurin inhibitors; CHF, congestive heart 
failure; CAD, coronary artery disease; CyA, cyclosporine; CV, cardiovascular; 
eGFR, estimated glomerular filtration rate; LVH, left ventricular hypertrophy; 
PTDM, post transplantation diabetes mellitus;  
Table 1. Modifiable risk factors for post transplant cardiovascular disease and 
strategies to address. 
AR, acute rejection; ACEi, angiotensin converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; AVF, arteriovenous fistula, CVD, 
cardiovascular disease; BP, blood pressure; CsA, cyclosporine; IS, 
immunosuppression; HLA, human leukocyte antigen; mTOR, mammalian 
target of rapamycin; LVH, left ventricular hypertrophy; RTR, renal transplant 
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recipients; RCT, randomised controlled trials; PTDM, post transplantation 
diabetes mellitus 
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